Biochemical efficacy and tolerability of allopurinol 300 - 600 mg/day versus benzbromarone 100 - 200 mg/day in GOUT patients

Not Applicable

Completed

• Conditions: Hyperuricemia, gout; Musculoskeletal Diseases; Arthropathies

• Registration Number: ISRCTN49563848
• Lead Sponsor: Medical Centre Leeuwarden (The Netherlands)

Brief Summary

2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18633127

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-02-26
• Study Completion: 2007-12-31
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

1. Diagnosis based on crystal evidence or otherwise meeting the American Rheumatology Association (ARA) criteria
2. Baseline serum urate measured
3. Baseline urinary urate excretion measured
4. Estimated creatinine clearance more than 50 mL/min

Exclusion Criteria

1. Contra-indication for study medication: allopurinol or benzbromarone
2. Poor compliance on allopurinol defined as serum oxipurinol less than 5 mg/L

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Success on study medication: tolerability and attainment of serum urate less than 0.30 mmol/

Secondary Outcome Measures

Name	Time	Method
<br> 1. Relative decrease of serum urate<br> 2. Adverse drug reactions profile<br> 3. Pharmacokinetic analysis of serum oxipurinol levels<br>